Exchange: NASDAQ·Updated 09:21 AM EDT
News
all
press releases
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity Technologiesread more...
Benzinga
More News
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational...
Business Wire
Why Is AMLX Stock Popping 14% After Hours?
Amylyx said the company said it will release top-line results from its late-stage trial of blood sugar drug avexitide on Tuesday.
Stocktwits
Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why
Amylyx Pharmaceuticals shares are trading higher Monday after the company scheduled a Phase 3 trial results readout for this week.read more...
Benzinga
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. Amylyxs senior management team will host a conference call and audio webcast at 8:00 a.m. ET. To...
Business Wire
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
Zacks
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
Zacks
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today reported financial and business results for the second quarter ended June 30, 2026. With the last participants final study visit recently completed, we are eagerly anticipating the expected topline data readout of the pivotal...
Business Wire
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its second quarter 2026 financial results on Thursday, August 6, 2026. Amylyxs senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company...
Business Wire
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July 3, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at...
PR Newswire

Advertisement|Remove ads.